Introduction: Lung cancer (LC) is the leading cause of death from cancer. Early diagnosis of LC is of paramount importance in terms of prognosis. The health authorities of most countries do not accept screening programs based on low dose chest computed tomography (LDCT), especially in Europe, since they are flawed by a high rate of false positive results, leading to a large number of invasive diagnostic procedures. These authorities advocated further research, including companion biological tests that could enhance the effectiveness of LC screening. The present project aims to validate early diagnosis of LC by detection and characterization of circulating tumor cells (CTCs) in a peripheral blood sample taken from a prospective cohort of patients with a high-risk of lung cancer.
BACKGROUND AND RATIONALE
Lung cancer (LC) is a leading cause of death from cancer. In France, LC is the 1 st and 2 nd cause of cancerrelated death in men and women, respectively, before prostate and colorectal cancers in men and after breast cancer in women [1] . In 2015 for the first time, the LC death rate in women overtook that of breast cancer in some European countries (UK & Poland) [2] .
Despite recent progress in therapeutic strategies, overall survival marginally decreased in the past 30 years and almost all patients with a symptomatic LC die of their disease within 5 years of diagnosis [3] [4] . The main reason is that surgery can be offered to less than 25% of patients since more than 75% of LC are diagnosed at advanced stages or are associated with comorbidities that contraindicate surgery [5] [6] .
Beside tobacco control, screening for early stage LC makes great sense. The National Lung Screening Trial (NLST), a methodologically rigorous trial conducted by the National Cancer Institute, provided evidence on the effect of low dose chest computed tomography (LDCT) screening on LC mortality [7] . This trial conducted in patients aged 55 to 74 years, current or former smokers (at least 30 pack-years) who quitted within fifteen years prior to recruitment, showed that LDCT screening decreased LC-specific mortality by at least 20% compared with chest X-ray screening. Several other LDCT screening trials are currently underway in Europe [8] [9] , but may not reach definite conclusions [10] Implementation and generalization of LDCT screening generates a substantial number of patients seeking advice for lung nodules of an undetermined nature and is therefore under debate [10] . False positive tests (i.e. identified at least one nodule > 4 mm in size), occur in close to one third of LDCT screening examinations and less than 3% of the patients who underwent the 3 rounds ultimately had a confirmed LC [7, [11] [12] [13] . In addition to generating anxiety and being costly these "incidental" nodules lead to multiple additional investigations that may per se be harmful to the patients. Even in North America, where LDCT screening is recommended, there is large debate on improving the LC screening efficiency by: (1) enhanced risk-based approaches, i.e. focusing on the appropriate high-risk patients, such as patients with chronic obstructive pulmonary disease (COPD) [14] [15] [16] [17] [18] [19] [20] [21] [22] , (2) setting more conservative thresholds for a positive nodule (e.g., > 6 mm) instead of the current "minimal size" of 4 mm [23] or (3) development of novel biomarkers measured in different biological samples (e.g., blood, urine) that improve the ability to predict lung cancer risk [24] . Non-invasive biomarkers under investigation include circulating tumor cells (CTCs) [25] [26] , circulating specific non-protein-coding RNA [27] [28] [29] and methylation of circulating DNA [30] .
Migration of CTCs into the blood stream is an early event of human carcinogenesis and tumors measuring around 300 microns can be associated with the presence of CTCs. Up to now, CTCs have been mainly analyzed in patients with an established diagnosis of cancer and used to monitor response to chemotherapy or too look for genomic alterations associated with a targeted therapy [25, [31] [32] . We recently showed that in high-risk patients, i.e. COPD patients, CTCs detected with the isolation by size of epithelial tumor cell (ISET) technique (RARECELLS®), were present up to 4 years before LC was identified on LDCT [26] . The CTCs detected had a heterogeneous expression of epithelial and mesenchymal markers, which was similar to the corresponding lung tumor phenotype [33] . No CTCs were detected in control smoking and non-smoking healthy individuals. With these preliminary results we demonstrated for the first time, that in high-risk patients, CTCs can be detected very early in the course of lung cancer and therefore, could be used as a screening tool in high-risk patients or be a biomarker that helps focusing LDCT efforts on individuals who are at highest risk for LC. It also might help in distinguishing benign from malignant lesions in the 20% of patients who show lung nodules on LDCT in screening programs. To confirm these hypotheses, a national prospective cohort study will be run with high-risk patients.
STUDY DESIGN AND OBJECTIVES
The AIR Project is a prospective, non-randomized, multicenter, double-blinded, cohort study that will evaluate CTCs as a screening tool for LC in a population at high-risk. Patients and investigators will be blinded to the results of the CTC analysis. At inclusion in the trial patients will undergo LDCT. In subjects without prevalent cancer at baseline, 2 additional LDCT, one and two years after baseline will be offered for search of incidental cases. Search for CTC will be performed at baseline along with LDCT (± 1 months of LDCT) and then once a year for 2 years along with LDCT. The study sponsor is the University Hospital of Nice (Centre Hospitalier Universitaire de Nice). Twenty-one sites throughout France will participate in this study.
The total duration is 4 years (inclusion period = 16 months; follow up = 1 to 4 years). ClinicalTrials.gov identifier NCT02500693.
The primary objective is to evaluate CTCs as a screening tool for LC in individuals at high-risk.
The secondary objectives are: i) to determine whether the presence of CTC may help to differentiate benign from malignant nodules in patients who show the presence of pulmonary nodules on LDCT, ii) to ask whether the presence of CTCs should prompt a special follow-up in a population at high-risk, iii) to study the miRNA signature from plasma and DNA methylation from circulating free DNA for prediction of LC in high-risk patients, iv) to study the relationship between the severity and distribution of emphysema and LC development, iv) to study the exposure of the cohort to professional carcinogens and v) to study the effect of screening on smoking behavior in smokers and to study the psychological impact of LDCT detection of lung nodules. 
STUDY POPULATION
The study population will consist of at least 600 patients who will be enrolled in 21 centers in France.
Inclusion and exclusion criteria are detailed in table 1.
The main inclusion criteria combine the NLST criteria [7] , i.e. age 55 years, tobacco pack-years ≥ 30, if a previous smoker, quit within 15 yr, and the presence of COPD.
We chose to add the "COPD" criteria since we aim to focus on a population at high-risk for LC. In fact, accumulating data suggest that the presence of COPD or emphysema, not considered in the NLST trial [7] , dramatically improves the selection process for LDCT cancer screening. For instance it was shown that after adjusting for sex, age and history of smoking, COPD is associated with a two-fold increase, and emphysema with a 3.5-fold increase in the LC risk [16, 18, 20, 34] .
INCLUSION AND PROCEDURES
Patients who meet all the inclusion criteria and none of the exclusion criteria will be enrolled by a designated investigator from each center, after signing written informed consent. Patient inclusion will be performed online (secured internet protocol) using a dedicated web based platform; the patient inclusion number will be allocated online with the format: 00-00/ center number/ number of inclusion. No randomization is planned in this study. Patients and investigators are blinded to the results of CTC analysis.
The study flow diagram is displayed in figure 1 . After the assessment for eligibility, enrolled patients will undergo a LDCT and a blood test for CTC search (CTCs detected with the ISET technique (RARECELLS®)) once a year for 3 consecutive years. Patients will be excluded from further screening when diagnosed with a lung cancer after a LDCT. All patients will be followed for at least one year after the last screening tour.
For low dose chest computed tomography, multidetectors scanners (≥16 detectors) will be used to ensure that the whole chest can be scanned in a single maximal breath hold. Unenhanced acquisitions (i.e. without contrast media) will use a low radiation exposure protocol consistent with lung cancer screening protocols with flexibility for making adjustments based on the patients' body mass index (BMI). The tube voltage will range from 100 to 140 kVp and the effective tube current time product will range from 20 to 60 mAs, according to the patient's BMI and on the CT apparatus. Each low dose CT will result in an average effective dose ≤ 1.5 mSv [35] [36] , for an average 70 kg adult. T corresponds to a dose length product (DLP) of about 75 mGy.cm.
During each round, 20 ml of peripheral blood on Streck tubes (Cell-Free DNA BCT® tubes, Streck, Omaha, USA) will be taken from each patient. These tubes will be sent at ambient temperature, to the coordinator center (Nice Biobank) within 48 hours. ISET will be carried out as previously described [26] . To compare the immediate delayed filtration, during the first round, the coordinator center (Nice) and the 4 other centers equipped with the ISET machines (Strasbourg, Toulouse, Nancy, Grenoble) will collect an additional 10 ml on an EDTA tube, which will be processed for immediate ISET filtration. The ISET non-colored filters, stored at 4°C, will be shipped later to the coordinator center for further CTC analysis.
MANAGEMENT OF RADIOLOGICALLY SIGNIFICANT INCIDENTAL FINDINGS
As in the NLST trial [7] , no formal recommendation will be made as to how a suspicious lesion should be managed in each center. For the management of a suspicious lesion all the centers involved in the present study will follow the strategies recommended by the French thoracic oncology groups [35] and the Fleischner society [37] . However, specific clinical presentations may fall outside of this general approach and require specific discussion in a multidisciplinary team meeting (MDT), which is the standard of care in all the centers involved in the present study. For patients for whom a suspicious lung nodule has been identified and in whom a final and definite diagnosis of cancer cannot be established because of premature death, a dedicated adjudication committee will review the entire medical chart and available documents to establish the probability of cancer.
OUTCOMES
The primary end point will be evaluated at the end of the follow-up period and will be represented by the rate of detection of CTCs in patients for whom lung cancer is detected during the study.
The secondary end points will include: (1) rate of detection of CTCs in the whole study population, (2) predictive value of CTC detection for the diagnosis of LC in patients identified as having a pulmonary nodule, (3) time span between detection of CTC and detection of lung cancer with LDCT and vice versa, (4) microRNA and DNA methylation profile in the study population, (5) smoking cessation rate and (6) pre/post-test changes in the Hospital Anxiety and Depression (HAD) scale.
COLLECTION OF DATA AND MONITORING
The usual demographic data will be recorded. The COPD phenotype will be recorded and thus will include measurement of airflow limitation by pulmonary function tests and assessment of COPD severity by the ABCD grading system (i.e. the ABCD grading system considers COPD symptoms along with the exacerbation frequency and severity, A is better, D is worse) [38] . Professional exposure to carcinogens will be evaluated with the RECAP questionnaire [39] . Lastly, the HAD scale will be measured during each protocol visit.
An electronic case report form (eCRF) has been created and is connected to a dedicated web-based biobank management module (BiobanK 06, Nice and Naeka, Grenoble France).
All chest-CT will be anonymized and stored in electronic (DICOM) format for further centralized analysis.
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ADVERSE EVENTS
An adverse event (AE) is defined as any untoward medical occurrence occurring during the participation of a subject in the trial, independently of the relationship with the study related interventions and procedures. A serious adverse event (SAE) is defined as any AE that results in death, is life-threatening, requiring in patient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/incapacity. Each adverse event (AE) must be judged by the investigator and the sponsor, for assessment of the severity of the causal link between AE and the procedure and the character expected or unexpected. A SUSAR (Suspected Unexpected Severe Adverse Reaction) is an adverse reaction that is both unexpected (not consistent with the study related interventions and procedures) and also meets the definition of a SAE. According to the law of 9 August 2004 of the Code of Public Health any occurrence of a SAE will immediately be reported to the sponsor. The sponsor will declare SAE likely to be related to biomedical research to the EC and to the French Agence Nationale du Medicament et des produits de Santé (ANSM) without delay and no later than 7 calendar days in case of death or lifethreatening and without delay and at the latest within 15 days for the other SAE.
STATISTICAL ANALYSIS AND SAMPLE SIZE
Statistical analyses will be performed on the whole study population, those with lung cancer (LC positives) and those without (LC negatives), detected by means of LDCT or by any others means. Data from both groups will be summarized separately for all criteria, demographics and baseline characteristics by descriptive statistics. A flow diagram presenting the progress of both groups throughout the study (enrollment, intervention allocation, follow-up and techniques for definite LC diagnosis) in each case will be displayed. The sensitivity and specificity of the ISET technique (detection of CTCs) for the detection of LC will be determined, and presented with their 95% CI based on the Wilson score calculation method.
Positive and negative predictive values (PPV, NPV) will be estimated assuming a 5% prevalence of LC in the studied population. The PPV and NPV of detection of CTCs for diagnosing LC in the subjects for whom clinically significant incidental findings will be revealed during the study course will be calculated, assuming a 25-35% prevalence of such findings in the studied population. In the LC positives group, descriptive 
DISCUSSION
The AIR Project is the first study to prospectively assess the value of CTC detection for lung cancer screening. We expect that in this high-risk population, CTC detection (via the ISET technology) will improve the detection rate of lung cancer, reduce the rate of false positive chest computed tomography, and act as a decision-making tool for patients with lung nodules of undetermined nature. Concurrent biomarker analysis (miRNA and DNA methylation) in blood samples may also offer the opportunity to validate a multimodal signature predictive of lung cancer in a high-risk population.
The main limitation of this study is that lung cancer related mortality will not be assessed as the primary outcome. Therefore, the power of this study may not be adequate to show a clinical benefit. Another limitation may be the detection of CTCs from a cancer developing in another organ (such as the bladder) in this high-risk population. However, ancillary methods are under development to better characterize the origin of the detected CTCs [33] . with chronic obstructive pulmonary disease (COPD). The volunteers will undergo yearly screening rounds for 3 years plus a one year follow-up. Each round will include LDCT plus peripheral blood sampling for CTC detection. Assuming 5% prevalence of LC in the studied population and a 10% dropout rate, a total of at least 600 volunteers will be enrolled.
Ethics and dissemination:
A consortium of 21 French university centers will run this study. The study sponsor is the University Hospital of Nice (Centre Hospitalier Universitaire de Nice). Ethics committee and ANSM (Ministry of Health) approvals were obtained in July 2015. The findings of the trial will be disseminated through peer-reviewed journals, and national and international conference presentations.
Trial registration number: NCT02500693
STRENGTHS AND LIMITATIONS OF THIS STUDY
This study focuses on an unmet need, i.e. identification of persons at high risk for lung cancer. Previous results from our group suggest that CTCs is an early event in LC and therefore could be used as a screening tool for LC. The main limitation is that lung cancer related mortality will not be assessed as the primary outcome. Therefore, the power of this study may not be adequate to show a clinical benefit Despite recent progress in therapeutic strategies, overall survival marginally decreased in the past 30 years and almost all patients with a symptomatic LC die of their disease within 5 years of diagnosis [3] [4] . The main reason is that surgery can be offered to less than 25% of patients since more than 75% of LC are diagnosed at advanced stages or are associated with comorbidities that contraindicate surgery [5] [6] .
Beside tobacco control, screening for early stage LC makes great sense. The National Lung Screening Trial (NLST), a methodologically rigorous trial conducted by the National Cancer Institute, provided evidence on the effect of low dose chest computed tomography (LDCT) screening on LC mortality [7] . This trial conducted in patients aged 55 to 74 years, current or former smokers (at least 30 pack-years) who quitted within fifteen years prior to recruitment, showed that LDCT screening decreased LC-specific mortality by at least 20% compared with chest X-ray screening. Several other LDCT screening trials are currently underway in Europe [8] [9] , but may not reach definite conclusions [10] Implementation and generalization of LDCT screening generates a substantial number of patients seeking advice for lung nodules of an undetermined nature and is therefore under debate [10] . False positive tests (i.e. identified at least one nodule ≥ 4 mm in size), occur in close to one third of LDCT screening examinations and less than 3% of the patients who underwent the 3 rounds ultimately had a confirmed LC [7, [11] [12] [13] . In addition to generating anxiety and being costly these "incidental" nodules lead to multiple additional investigations that may per se be harmful to the patients. Even in North America, where LDCT screening is recommended, there is large debate on improving the LC screening efficiency by: (1) enhanced risk-based approaches, i.e. focusing on the appropriate high-risk patients, such as patients with chronic obstructive pulmonary disease (COPD) [14] [15] [16] [17] [18] [19] [20] [21] [22] , (2) setting more conservative thresholds for a positive nodule (e.g., ≥ 6 mm) instead of the current "minimal size" of 4 mm [23] or (3) development of novel biomarkers measured in different biological samples (e.g., blood, urine) that improve the ability to predict lung cancer risk [24] or to distinguish benign from malignant screen-detected nodules. Non-invasive biomarkers under investigation include circulating tumor cells (CTCs) [25] [26] , circulating specific nonprotein-coding RNA [27] [28] [29] and methylation of circulating DNA [30] . Migration of CTCs into the blood stream is an early event of human carcinogenesis and tumors measuring around 300 microns can be associated with the presence of CTCs. Up to now, CTCs have been mainly analyzed in patients with an established diagnosis of cancer and used to monitor response to chemotherapy or to look for genomic alterations associated with a targeted therapy [25, [31] [32] . We recently showed that in high-risk patients, i.e. COPD patients, CTCs detected with the isolation by size of epithelial tumor cell (ISET) technique (RARECELLS®), were present up to 4 years before LC was identified on LDCT [26] . The CTCs detected had a heterogeneous expression of epithelial and mesenchymal markers, which was similar to the corresponding lung tumor phenotype [33] . No CTCs were detected in control smoking and non-smoking healthy individuals. With these preliminary results we demonstrated for the first time, that in high-risk patients, CTCs can be detected very early in the course of lung cancer and therefore, could be used as a screening tool in high-risk patients or be a biomarker that helps focusing LDCT efforts on individuals who are at highest risk for LC. It also might help in distinguishing benign from malignant lesions in the 20% of patients who show lung nodules on LDCT in screening programs. To confirm these hypotheses, a national prospective cohort study will be run with high-risk patients.
STUDY DESIGN AND OBJECTIVES
The AIR Project is a prospective, non-randomized, multicenter, double-blinded, cohort study that will evaluate CTCs as a screening tool for LC in a population at high-risk. Study participants and investigators will be blinded to the results of the CTC analysis. At inclusion in the trial study participants will undergo LDCT. In participants without prevalent cancer at baseline, 2 additional LDCT, one and two years after baseline will be offered for search of incidental cases. Search for CTC will be performed at baseline along with LDCT (± 1 months of LDCT) and then once a year for 2 years along with LDCT. The study sponsor is the University Hospital of Nice (Centre Hospitalier Universitaire de Nice). Twenty-one sites throughout France will participate in this study. The total duration is 4 years (inclusion period = 16 months; follow up = 1 to 4 years). ClinicalTrials.gov identifier NCT02500693.
The primary objective is to determine the sensitivity, specificity, PPV and NPV of CTCs for the early detection of LC in a cohort of asymptomatic participants at high risk for LC.
The secondary objectives are: i) to determine whether CTC and/or miRNA signature from plasma and/or DNA methylation from circulating free DNA can distinguish benign from malignant screen-detected pulmonary nodules in persons at high risk for LC, ii) to check whether the presence of CTCs should prompt a special follow-up in a population at high-risk of LC with negative LDCT screening, iii) to study the relationship between the severity and distribution of emphysema and LC development, iv) to study the exposure of the cohort to professional carcinogens and v) to study the effect of screening on smoking behavior in smokers and to study the psychological impact of LDCT detection of lung nodules. 
STUDY POPULATION
We chose to add the "COPD" criteria since we aim to focus on a population at high-risk for LC. In fact, accumulating data suggest that the presence of COPD or emphysema, not considered in the NLST trial [7] , dramatically improves the selection process for LDCT cancer screening. For instance it was shown that after adjusting for sex, age and history of smoking, COPD is associated with a two-fold increase, and emphysema with a 3.5-fold increase in the LC risk [16, 18, 20, 34, 35] .
INCLUSION AND PROCEDURES
For low dose chest computed tomography, multidetectors scanners (≥16 detectors) will be used to ensure that the whole chest can be scanned in a single maximal breath hold. Unenhanced acquisitions (i.e. without contrast media) will use a low radiation exposure protocol consistent with lung cancer screening protocols with flexibility for making adjustments based on the patients' body mass index (BMI). The tube voltage will range from 100 to 140 kVp and the effective tube current time product will range from 20 to 60 mAs, according to the patient's BMI and on the CT apparatus. Each low dose CT will result in an average effective dose ≤ 1.5 mSv [36] [37] , for an average 70 kg adult. T corresponds to a dose length product (DLP) of about 75 mGy.cm.
MANAGEMENT OF RADIOLOGICALLY SIGNIFICANT INCIDENTAL FINDINGS
As in the NLST trial [7] , no formal recommendation will be made as to how a suspicious lesion should be managed in each center. For the management of a suspicious lesion all the centers involved in the present study will follow the strategies recommended by the French thoracic oncology groups [35] and the Fleischner society [38] . However, specific clinical presentations may fall outside of this general approach and require specific discussion in a multidisciplinary team meeting (MDT), which is the standard of care in all the centers involved in the present study.
OUTCOMES
For patients for whom a suspicious lung nodule has been identified and in whom a final and definite diagnosis of cancer cannot be established because of premature death, a dedicated adjudication committee will review the entire medical chart and available documents to establish the probability of cancer.
Two interim analysis are planned, one at the end of the first screening tour and one at the end of the second one, in order to check whether the number of cases with CTCs is significantly higher than we would expect.
COLLECTION OF DATA AND MONITORING
The usual demographic data will be recorded. The COPD phenotype will be recorded and thus will include measurement of airflow limitation by pulmonary function tests and assessment of COPD severity by the ABCD grading system (i.e. the ABCD grading system considers COPD symptoms along with the exacerbation frequency and severity, A is better, D is worse) [39] . Professional exposure to carcinogens will be evaluated with the RECAP questionnaire [40] . Lastly, the HAD scale will be measured during each protocol visit. An electronic case report form (eCRF) has been created and is connected to a dedicated web-based biobank management module (BiobanK 06, Nice and Naeka, Grenoble France).
Quality control will be done by clinical research monitors appointed by the sponsor. The nature and frequency of monitoring will be based on the rate of inclusion. They will check for the accuracy and completeness of the Case Report Form entries, source documents and other trial-related records, they will verify that written informed consent was obtained and that in each center, the trial is in compliance with the currently approved protocol/amendment(s), with good clinical practice, and with the applicable regulatory requirement(s).
ADVERSE EVENTS
An adverse event (AE) is defined as any untoward medical occurrence occurring during the participation of a subject in the trial, independently of the relationship with the study related interventions and 
STATISTICAL ANALYSIS AND SAMPLE SIZE
Statistical analyses will be performed on the whole study population, those with lung cancer (LC positives) and those without (LC negatives), detected by means of LDCT or by any others means. Data from both groups will be summarized separately for all criteria, demographics and baseline characteristics by descriptive statistics. A flow diagram presenting the progress of both groups throughout the study (enrollment, intervention allocation, follow-up and techniques for definite LC diagnosis) in each case will be displayed. The sensitivity and specificity of the ISET technique (detection of CTCs) for the detection of LC will be determined, and presented with their 95% CI based on the Wilson score calculation method. Positive and negative predictive values (PPV, NPV) will be estimated assuming a 5% prevalence of LC in the studied population. The PPV and NPV of detection of CTCs for diagnosing LC in the participants for whom clinically significant incidental findings will be revealed during the study course will be calculated, assuming a 25-35% prevalence of such findings in the studied population. In the LC positives group, descriptive statistics describing the temporal relationship (first sign suggestive of LC) and positivity of CTC detection will be provided. Test assumptions will be verified before analyses. P-values below 0.05 will be considered to denote statistical significance. Based on the prevalence (baseline screening round) and incidence (repeat screening rounds) of LC in this high risk population and considering a 10% dropout rate, if we aim to study a total of 25-35 detected LC, including baseline and repeat screening rounds, we need to enroll a total of 600 patients. 
ETHICAL AND REGULATORY CLEARANCES
DISCUSSION
The AIR Project is the first study to prospectively assess the value of CTC detection for lung cancer screening. We expect that in this high-risk population, CTC detection (via the ISET technology) will improve the detection rate of lung cancer and perhaps also reduce the rate of false positive chest computed tomography by distinguishing benign from malignant screen-detected pulmonary nodules in persons at high risk for LC. Concurrent biomarker analysis (miRNA and DNA methylation) in blood samples may also offer the opportunity to validate a multi-modal signature predictive of lung cancer in a high-risk populations with screen detected pulmonary nodules.
The main limitation of this study is that lung cancer related mortality will not be assessed as the primary outcome. Therefore, the power of this study may not be adequate to show a clinical benefit. Another limitation may be the detection of CTCs from a cancer developing in another organ (such as the bladder) in this high-risk population. However, ancillary methods are under development to better characterize the origin of the detected CTCs [33] . The study participants will undergo yearly screening rounds for 3 years plus a one year follow-up. Each round will include LDCT plus peripheral blood sampling for CTC detection. Assuming 5% prevalence of LC in the studied population and a 10% dropout rate, a total of at least 600 volunteers will be enrolled.
Ethics and dissemination:
The study sponsor is the University Hospital of Nice. The study was approved for
France by the ethical committee Sud-Méditerranée V and the ANSM (Ministry of Health) in July 2015. The findings of the trial will be disseminated through peer-reviewed journals, and national and international conference presentations.
ClinicalTrials.gov identifier : NCT02500693
STRENGTHS AND LIMITATIONS OF THIS STUDY
This study focuses on an unmet need, i.e. identification of persons at high risk for lung cancer (LC).
Previous results from our group suggest that circulating tumor cells (CTCs) is an early event in LC and therefore could be used as a screening tool for LC.
The main limitation is the insufficient power of this study to show a clinical benefit (i.e. reduction of LC mortality)
Another limitation may be the detection of CTCs from a cancer developing in another organ (such as the bladder) in this high-risk population, although ancillary methods are under development to better characterize the origin of the detected CTCs 
BACKGROUND AND RATIONALE
Beside tobacco control, screening for early stage LC makes great sense. The National Lung Screening Trial (NLST), a methodologically rigorous trial conducted by the National Cancer Institute, provided evidence on the effect of low dose chest computed tomography (LDCT) screening on LC mortality [7] . This trial conducted in patients aged 55 to 74 years, current or former smokers (at least 30 pack-years) who quitted within fifteen years prior to recruitment, showed that LDCT screening decreased LC-specific mortality by at least 20% compared with chest X-ray screening. Several other LDCT screening trials are currently underway in Europe [8] [9] , but may not reach definite conclusions [10] Implementation and generalization of LDCT screening generates a substantial number of patients seeking advice for lung nodules of an undetermined nature and is therefore under debate [10] . False positive tests (i.e. identified at least one nodule ≥ 4 mm in size), occur in close to one third of LDCT screening examinations and less than 3% of the patients who underwent the 3 rounds ultimately had a confirmed LC [7, [11] [12] [13] . In addition to generating anxiety and being costly these "incidental" nodules lead to multiple additional investigations that may per se be harmful to the patients. Even in North America, where LDCT screening is recommended, there is large debate on improving the LC screening efficiency by: (1) enhanced risk-based approaches, i.e. focusing on the appropriate high-risk patients, such as patients with chronic obstructive pulmonary disease (COPD) [14] [15] [16] [17] [18] [19] [20] [21] [22] , (2) setting more conservative thresholds for a positive nodule (e.g., ≥ 6 mm) instead of the current "minimal size" of 4 mm [23] or (3) development of novel biomarkers measured in different biological samples (e.g., blood, urine) that improve the ability to predict lung cancer risk [24] or to distinguish benign from malignant screen-detected nodules. Non-invasive biomarkers under investigation include circulating tumor cells (CTCs) [25] [26] , circulating specific nonprotein-coding RNA [27] [28] [29] and methylation of circulating DNA [30] . Migration of CTCs into the blood stream is an early event of human carcinogenesis and tumors measuring around 300 microns can be associated with the presence of CTCs. Up to now, CTCs have been mainly analyzed in patients with an established diagnosis of cancer and used to monitor response to chemotherapy or to look for genomic alterations associated with a targeted therapy [25, [31] [32] . We recently showed that in high-risk patients, i.e. COPD patients, CTCs detected with the isolation by size of epithelial tumor cell (ISET) technique (RARECELLS®), were present up to 4 years before LC was identified on LDCT [26] . The CTCs detected had a heterogeneous expression of epithelial and mesenchymal markers, which was similar to the corresponding lung tumor phenotype [33] . No CTCs were detected in control smoking and non-smoking healthy individuals. With these preliminary results we demonstrated for the first time, that in high-risk patients, CTCs can be detected very early in the course of lung cancer and therefore, could be used as a screening tool in high-risk patients or be a biomarker that helps focusing LDCT efforts on individuals who are at highest risk for LC. It also might help in distinguishing benign from malignant lesions in the patients who show lung nodules on LDCT in screening programs. To confirm these hypotheses, a national prospective cohort study will be run with high-risk participants.
STUDY DESIGN AND OBJECTIVES
The AIR Project is a prospective, non-randomized, multicenter, double-blinded, cohort study that evaluates
CTCs as a screening tool for LC in a population at high-risk. Study participants and investigators will be blinded to the results of the CTC analysis. At inclusion in the trial study participants will undergo LDCT. In participants without prevalent cancer at baseline, 2 additional LDCT, one and two years after baseline will be offered for search of incidental cases. Search for CTC will be performed at baseline along with LDCT (± 1 months of LDCT) and then once a year for 2 years along with LDCT. The study sponsor is the University Hospital of Nice (Centre Hospitalier Universitaire de Nice). Twenty-one sites throughout France will participate in this study. The total duration is 4 years (inclusion period = 16 months; follow up = 1 to 4 years). ClinicalTrials.gov identifier NCT02500693.
The secondary objectives are: i) to determine whether CTC and/or miRNA signature from plasma and/or DNA methylation from circulating free DNA can distinguish benign from malignant screen-detected pulmonary nodules in asymptomatic persons at high risk for LC, ii) to check whether the presence of CTCs should prompt a special follow-up in a population at high-risk of LC with negative LDCT screening, iii) to study the relationship between the severity and distribution of emphysema and LC development, iv) to study the exposure of the cohort to professional carcinogens and v) to study the effect of screening on smoking behavior in smokers and to study the psychological impact of LDCT detection of lung nodules. 
STUDY POPULATION
The study population will consist of at least 600 participants who will be enrolled in 21 centers in France.
We chose to add the "COPD" criteria since we aim to focus on a population at high-risk for LC. In fact, accumulating data suggest that the presence of COPD or emphysema, not considered in the NLST trial [7] , dramatically improves the selection process for LDCT cancer screening. For instance it was shown that after adjusting for sex, age and history of smoking, COPD is associated with a two-fold increase, and emphysema with a three-fold increase in the LC risk [16, 18, 20, 34, 35] .
INCLUSION AND PROCEDURES
Participants who meet all the inclusion criteria and none of the exclusion criteria will be enrolled by a designated investigator from each center, after signing written informed consent. Inclusion will be performed online (secured internet protocol) using a dedicated web based platform; the participant's inclusion number will be allocated online with the format: 00-00/ center number/ number of inclusion. No randomization is planned in this study. Participants and investigators are blinded to the results of CTC analysis.
The study flow diagram is displayed in figure 1 . After the assessment for eligibility, enrolled participants will undergo a LDCT and a blood test for CTC search (CTCs detected with the ISET technique (RARECELLS®)) once a year for 3 consecutive years. Participants will be excluded from further screening when diagnosed with a lung cancer after a LDCT. All participants will be followed for at least one year after the last screening tour.
For low dose chest computed tomography, multidetectors scanners (≥16 detectors) will be used to ensure that the whole chest can be scanned in a single maximal breath hold. Unenhanced acquisitions (i.e. without contrast media) will use a low radiation exposure protocol consistent with lung cancer screening protocols with flexibility for making adjustments based on the participants' body mass index (BMI). The tube voltage will range from 100 to 140 kVp and the effective tube current time product will range from 20 to 60 mAs, according to the participants' BMI and on the CT apparatus. Each low dose CT will result in an average effective dose ≤ 1.5 mSv [36] [37] , for an average 70 kg adult. T corresponds to a dose length product (DLP) of about 75 mGy.cm.
During each round, 20 ml of peripheral blood on Streck tubes (Cell-Free DNA BCT® tubes, Streck, Omaha, USA) will be taken from each participant. These tubes will be sent at ambient temperature, to the coordinator center (Nice Biobank) within 48 hours. ISET will be carried out as previously described [26] . To compare the immediate delayed filtration, during the first round, the coordinator center (Nice) and the 4 other centers equipped with the ISET machines (Strasbourg, Toulouse, Nancy, Grenoble) will collect an additional 10 ml on an EDTA tube, which will be processed for immediate ISET filtration. The ISET noncolored filters, stored at 4°C, will be shipped later to the coordinator center for further CTC analysis.
MANAGEMENT OF RADIOLOGICALLY SIGNIFICANT INCIDENTAL FINDINGS
OUTCOMES
The primary end point will be evaluated at the end of the follow-up period and will be represented by the rate of detection of CTCs in participants for whom lung cancer is detected during the study.
The secondary end points will include: (1) rate of detection of CTCs in the whole study population, (2) predictive value of CTC detection for the diagnosis of LC in participants identified as having a pulmonary nodule, (3) time span between detection of CTC and detection of lung cancer with LDCT and vice versa, (4) microRNA and DNA methylation profile in the study population, (5) smoking cessation rate and (6) pre/post-test changes in the Hospital Anxiety and Depression (HAD) scale.
For participants for whom a suspicious lung nodule has been identified and in whom a final and definite diagnosis of cancer cannot be established because of premature death, a dedicated adjudication committee will review the entire medical chart and available documents to establish the probability of cancer.
COLLECTION OF DATA AND MONITORING
ADVERSE EVENTS
STATISTICAL ANALYSIS AND SAMPLE SIZE
Statistical analyses will be performed on the whole study population, those with lung cancer (LC positives) and those without (LC negatives), detected by means of LDCT or by any others means. Data from both groups will be summarized separately for all criteria, demographics and baseline characteristics by descriptive statistics. A flow diagram presenting the progress of both groups throughout the study (enrollment, intervention allocation, follow-up and techniques for definite LC diagnosis) in each case will be displayed. The sensitivity and specificity of the ISET technique (detection of CTCs) for the detection of LC will be determined, and presented with their 95% CI based on the Wilson score calculation method. Positive and negative predictive values (PPV, NPV) will be estimated assuming a 5% prevalence of LC in the studied population. The PPV and NPV of detection of CTCs for diagnosing LC in the participants for whom clinically significant incidental findings will be revealed during the study course will be calculated, assuming a 25-35% prevalence of such findings in the studied population. In the LC positives group, descriptive statistics describing the temporal relationship (first sign suggestive of LC) and positivity of CTC detection will be provided. Test assumptions will be verified before analyses. P-values below 0.05 will be considered to denote statistical significance. Based on the prevalence (baseline screening round) and incidence (repeat screening rounds) of LC in this high risk population and considering a 10% dropout rate, if we aim to study a total of 25-35 detected LC, including baseline and repeat screening rounds, we need to enroll a total of 600 participants. 
ETHICS, REGULATORY CLEARANCES AND DISSEMINATION
DISCUSSION
The AIR Project is the first study to prospectively assess the value of CTC detection for lung cancer screening. We expect that in this high-risk population, CTC detection (via the ISET technology) will improve the detection rate of lung cancer and perhaps also reduce the rate of false positive chest computed tomography by distinguishing benign from malignant screen-detected pulmonary nodules in persons at high risk for LC. Concurrent biomarker analysis (miRNA and DNA methylation) in blood samples may also offer the opportunity to validate a multi-modal signature predictive of lung cancer in a high-risk populations with screen detected pulmonary nodules. The main limitation of this study is that lung cancer related mortality will not be assessed as the primary outcome. Therefore, the power of this study may not be adequate to show a clinical benefit. Another limitation may be the detection of CTCs from a cancer developing in another organ (such as the bladder) in this high-risk population. However, ancillary methods are under development to better characterize the origin of the detected CTCs [33] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
